SEC Form 4 · accession 0001209191-17-041194
ImmunityBio, Inc. · IBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Gorlin
Director
Period of report
Jun 20, 2017
Accepted (ET)
Jun 21, 2017 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326110
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 20, 2017 | S | 20,000 | $7.43 | D | 409,725 | D | |
| Common Stock | Jun 20, 2017 | S | 20,000 | $8.13 | D | 389,725 | D | |
| Common Stock | holding | — | — | — | 521,720 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2016.